GT Biopharma will combine every 25 common shares into one on September 8, while eliminating Series A through Series K Preferred Stock. The change matters to investors because outstanding convertible securities, warrants, Options and restricted stock will be adjusted, while fractional interests will be sold for holders’ pro rata share of the proceeds.
Key Highlights
- Authorized Capital Stock will fall from 265,000,000 shares to 26,500,000 shares.
- Series A through Series K Preferred Stock will be removed from GT Biopharma’s charter, with no such shares outstanding immediately before the action.
- Split-adjusted trading of GT Biopharma’s Common Stock will begin at market open on September 8, 2026.
GT Biopharma, Inc. (NASDAQ: GTBP) will combine every 25 issued and outstanding Common Stock shares into one share under a 1-for-25 reverse stock split.
Preferred Stock Eliminated
GT Biopharma filed certificates removing the charter provisions tied to Series A, Series B, Series C, Series D, Series E, Series F, Series G, Series H, Series I, Series J-1 and Series K Preferred Stock. All outstanding Series C Preferred Stock was converted in accordance with its terms on September 2, 2026. No shares from any of the eliminated preferred stock series were outstanding immediately before the certificates were filed. The certificates were executed by Chief Financial Officer Alan Urban on September 2, 2026.
Authorized Capital Reset
The company’s authorized Common Stock will be reduced to 25,000,000 shares, while authorized preferred stock will be set at 1,500,000 shares. Total authorized capital stock will move from 265,000,000 shares to 26,500,000 shares. The Par Value of Common Stock will remain $0.001 per share.
September 8 Trading Change
The number of Common Stock shares covered by those instruments will be adjusted proportionately, and their conversion or exercise prices will be adjusted under the relevant security terms and Equity incentive plans. Fractional shares will not be issued. The new CUSIP number for Common Stock will be 36254L 407. GT Biopharma stockholders approved authority for a reverse split ranging from 1-for-10 to 1-for-30 at the annual meeting held on August 14, 2026, and the board approved the final 1-for-25 ratio on August 27, 2026.




Please wait processing your request...